drugset
drugset / Trial / NCT04054206

Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers

NCT04054206 ↗

Phase 1 Completed 12 enrolled MediciNova
RandomizedCrossoverOpen-labelTreatment

Summary

This study will investigate the PK, relative bioavailability, safety, and tolerability of the extended release (ER) 50 mg MN-166 (ibudilast) tablet formulation as compared to the intermediate-release (IR) capsule formulation of MN-166 (ibudilast) and to examine the effect of food on the pharmacokinetics of the ER formulation.

Timeline

Start
2019-06-24
Primary completion
2019-07-17
Completion
2020-05-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ibudilast Small molecule 50 mg Oral

Indications

No indication recorded.